Epilepside kişiye özel genetik tedavi yaklaşımları

Epilepsi dünyada %1 prevelansa sahip olduğu öngörülen, yaygın ve ciddi nörolojik bir durumdur. Epidemiyolojik çalışmalarda epilepsili hastaların %20-40’ının, antiepileptik tedaviye dirençli olduğu belirtilmiştir. Farmakolojik tedaviye direnç epilepsi tedavisinde en önemli problemlerden biri olmaktadır. Epilepsideki bu direncin altında yatan mekanizmalar açık değildir ancak çeşitli muhtemel hipotezler belirlenmiştir. Günümüzdeki çalışmalar, gen tedavileri ve kişiye özgü tedaviler üzerinde yoğunlaşmaktadır. Bu derlemede epilepsi tedavisinde yeni hedef moleküllerin bulunabilmesi açısından proteomik araştırmaların önemi tartışılmaktadır.

Individual genetic treatment approaches in epilepsy

Epilepsy is the most common serious neurological condition in the world, with an estimated prevalence of 1% of the population. Epidemiological data indicate that 20-40% of the patients with epilepsy are refractory to treatment with antiepileptic drugs. Pharmacoresistance is a major problem in the treatment of epilepsy. The mechanisms underlying pharmaco resistance in epilepsy are unclear, but several plausible hypotheses have emerged. Present studies are concentrated on indivudual treatments and gene therapies. In this review, importance of proteomics researchs in terms of find out the new molecular targets for the treatment of epilepsy were discussed.

Kaynakça

1. Seino M. Classification criteria of epileptic seizures and syndromes. Epilepsy Res 2006;1:27-33.

2. Availablefrom:WHO,2009.(http://www.who.int/mediacentre/ factsheets/fs999/en/)

3. Zupec-Kania BA, Spellman E. An overview of the ketogenic diet for pediatric epilepsy.Nutr Clin Pract 2008;23:589-96.

4. Altay EE, Bilir E. Demans ve Epilepsi. DEMANS DİZİSİ 1999;4: 116-28.

5. Öztekin-Subutay N. Epilepsi Fizyopatolojisi. Nöroloji Dergisi 2004; 2:2.

6. Bertram EH. Temporal lobe epilepsy: where do the seizures really begin? Epilepsy Behav 2009;1:32-7.

7. Available from: http://hastane.harran.edu.tr/norofatih/epilepsi. pdf

8. Bolluk B,Yiğit A. Epileptolojide Sınıflamalar. T Klin J Neur 2004;2: 103.

9. Kostopoulos G. K. Spike-and-wave discharges of absence seizures as a transformation of sleep spindles: the continuing development of a hypothesis. Clin Neurophysiol 2000:111;2: 27–S38.

10. Shin HS, Lee J, Song I. Genetic studies on the role of T-type Ca2+ channels in sleep and absence epilepsy. CNS Neurol Disord Drug Targets 2006;5:629-38.

11. Kim D, Song I, Keum S, et al. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking α1G T-type Ca2+ channels. Neuron 2001;31:35–45.

12. Porter JT, Nieves D. Presynaptic GABAB receptors modulate thalamic excitation of inhibitory and excitatory neurons in the mouse barrel cortex. J. Neurophysiol 2004;92:2762–70.

13. Futatsugi Y, Riviello JJ. Mechanisms of generalized absence epilepsy. Brain Dev 1998;20:75–9.

14. Arida RM, Scorza FA, Scorza CA, Cavalheiro EA.Is physical activity beneficial for recovery in temporal lobe epilepsy? Evidences from animal studies. Neurosci Biobehav Rev 2008;18.

15. Bilginer B, Akalan N. Temporal Lobe Epilepsies. Türk Nöroşirürji Dergisi 2006:3:156-9.

16. Availablefrom:http://en.wikipedia.org/wiki/Temporal_lobeepilepsy

17. Bethmann K, Fritschy JM, Brandt C, Löscher W. Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis 2008;31: 169-87.

18. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation, Ex Neurol 1969; 25:295– 330.

19. Bertram, 2007 E. The relevance of kindling for human epilepsy, Epilepsia 2007;2:65–74.

20. Nolte MW, Löscher W, Herden C, Freed WJ, Gernert M. Benefits and risks of intranigral transplantation of GABA-producing cells subsequent to the establishment of kindling-induced seizures. Neurobiol Dis 2008;31: 342-54.

21. Kalynchuk LE, Pinel JP, Meaney MJ. Serotonin receptor binding and mRNA expression in the hippocampus of fearful amygdala-kindled rats. Neurosci Lett 2006;396:38-43.

22. van Vliet EA, van Schaik R, et al . Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia 2008;49:1151-9.

23. Liefaard LC, Ploeger BA, Molthoff CF, et al. Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography. Epilepsia 2009;50:88- 98.

24. Huang ZL, Zhou Y, Xiao B, et al. Proteomic screening of postsynaptic density proteins related with temporal lobe epilepsy. Zhonghua Yi Xue Za Zhi 2008;9;88:3205-9

25. Dyck RH, Bogoch II, Marks A, Melvin NR, Teskey GC. Enhanced epileptogenesis in S100B knockout mice. Brain Res Mol Brain Res 2002; 106:22-9.

Kaynak Göster